Advances in precision gene editing for liver fibrosis: From technology to therapeutic applications - 23/07/24
Abstract |
This review presents a comprehensive exploration of gene editing technologies and their potential applications in the treatment of liver fibrosis, a condition often leading to serious complications such as liver cancer. Through an in-depth review of current literature and critical analysis, the study delves into the intricate signaling pathways underlying liver fibrosis development and examines the promising role of gene editing in alleviating this disease burden. Gene editing technologies offer precise, efficient, and reproducible tools for manipulating genetic material, holding significant promise for basic research and clinical practice. The manuscript highlights the challenges and potential risks associated with gene editing technology. By synthesizing existing knowledge and exploring future perspectives, this study aims to provide valuable insights into the potential of precision gene editing to combat liver fibrosis and its associated complications, ultimately contributing to advances in liver fibrosis research and therapy.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
This review delves into the precision of techniques like CRISPR/Cas9 and their potential in clinical applications, providing a comprehensive analysis of their therapeutic promise and challenges.
This review delves into the precision of techniques like CRISPR/Cas9 and their potential in clinical applications, providing a comprehensive analysis of their therapeutic promise and challenges.Le texte complet de cet article est disponible en PDF.
Highlights |
• | CRISPR/Cas9 and TALEN technologies target key genes (ADAM9, BMP9, Gp96) to mitigate liver fibrosis. |
• | Innovative delivery systems enhance precision and efficacy in liver-targeted gene therapies. |
• | Ethical considerations and regulatory frameworks are pivotal for the safe clinical application of gene editing technologies. |
Abbreviations : ECM, HSCs, HSC, HR, ZFN, TALEN, CRISPR, DSBs, NHEJ, HDR, TALEs, PE, PegRNA, RT, NCas9, Cas9, PAM, CrRNA, TracrRNA, SCD, TDT, DSBs, TGF-β, PDGF, TGF-β, ET-1, PTEN, PLK1, IL-10, AMMs
Keywords : Liver fibrosis, Gene editing, CRISPR/Cas9, Therapeutic targets, Precision medicine
Plan
Vol 177
Article 117003- août 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?